Tags : Australia

Biosimilars

Biocon and Mylan Launch Fulphila (biosimilar, Pegfilgrastim) in Australia

Shots: The companies launched Fulphila, a biosimilar referencing Neulasta (pegfilgrastim) in Australia. The biosimilar received TGA’s approval to treat cancer patients following the CT, to decrease the duration of neutropenia and to reduce the incidence of infections, as manifested by febrile neutropenia The approval is based on analytical, clinical and nonclinical data which demonstrated that […]Read More

Biosimilars

Celltrion Signs an Exclusive Co-Marketing Agreement with Juno in Australia

Shots: Juno to provide sales promotion and hospital contracting services to Australian Hospital market customers and will co-market Herzuma (biosimilar, trastuzumab) and Truxima (biosimilar, rituximab) with Celltrion in Australia  The focus of the agreement is to market globally biosimilar brands to Australian Healthcare professionals and patients Herzuma (CT-P6, biosimilar, trastuzumab) is a mAb targeting the […]Read More

Biosimilars

Mylan and Biocon Launch Ogivri (biosimilar, trastuzumab) in Australia

Shots: Ogivri is the first biosimilar to Herceptin (trastuzumab) to be approved and launched in Australia for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer and will be available on the Pharmaceutical Benefits Scheme The TGA’s approval of Ogivri is based on data which demonstrated bio-similarity to Herceptin with no clinically meaningful differences […]Read More

Biosimilars Pharma

Celltrion’s Herzuma (Herceptin biosimilar) Receives Marketing Approval in Australia

Shots: Herzuma is first biosimilar approved in Australia for the treatment of early breast cancer, locally advanced or metastatic or advance gastric cancer Including Herzuma Celltrion has three biosimilar for Australia, Remsima for autoimmune disease, Truxima for blood cancer approved in Aug 2015 and April 2018 respectively Celltrion plans to launch Herzuma in Australia after […]Read More